UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study

Leukemia research, 2017-04, Vol.55, p.S58-S58

2017

Volltextzugriff (PDF)

O-020 Erythropoietin alpha therapy in 1110 lower-risk MDS patients: A real life survey from the network of regional Italian MDS Registries

Leukemia research, 2013-05, Vol.37, p.S18-S18

2013

Volltextzugriff (PDF)

P104 Prognostic role of transfusion requirement in myelodysplastic syndromes

Leukemia research, 2007, Vol.31, p.S96-S96

2007

Volltextzugriff (PDF)

P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register

Leukemia research, 2007, Vol.31, p.S41-S42

2007

Volltextzugriff (PDF)

93 - Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study

Leukemia research, 2017-04, Vol.55, p.S58-S58

2017

Volltextzugriff (PDF)

In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity

Leukemia, 1988, Vol.2 (1), p.50-54

1988

Volltextzugriff (PDF)

Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin

British journal of haematology, 1990-05, Vol.75 (1), p.34-40

1990

Volltextzugriff (PDF)

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors

Blood, 1990-10, Vol.76 (7), p.1349-1354

1990

Volltextzugriff (PDF)

Scleroderma and hairy-cell leukemia

European journal of haematology, 1994-03, Vol.52 (3), p.189-190

1994

Volltextzugriff (PDF)

Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry

Blood, 2004-11, Vol.104 (11), p.1432-1432

2004

Volltextzugriff (PDF)

Effect of alpha-interferon on the immune system of patients with hairy cell leukemia

Leukemia, 1987-04, Vol.1 (4), p.377-379

1987

Volltextzugriff (PDF)

Lymphokine activated killer (LAK) activity in lymphoproliferative disorders

Bone marrow transplantation (Basingstoke), 1989-01, Vol.4 Suppl 1, p.153-155

1989

Volltextzugriff (PDF)

Defective Lymphokine-Activated Killer Cell Generation and Activity in Acute Leukemia Patients With Active Disease

Blood, 1991-08, Vol.78 (4), p.1041-1046

1991

Volltextzugriff (PDF)

Autocrine or paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia

Nouvelle revue francaise d'hematologie, 1988, Vol.30 (5-6), p.339

1988

Volltextzugriff (PDF)

Immunoregulatory T-cell defects in B-cell chronic lymphocytic leukemia: cause or consequence of the disease? The contributory role of decreased availability of interleukin 2 (IL-2)

Blood cells, 1987, Vol.12 (2), p.399

1987

Volltextzugriff (PDF)

Treatment of hairy-cell leukaemia with α-interferon (α-IFN)

European journal of cancer & clinical oncology, 1988-02, Vol.24 (2), p.195-200

1988

Volltextzugriff (PDF)

Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease

Blood, 1991-08, Vol.78 (4), p.1041-1046

1991

Volltextzugriff (PDF)

Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells

European journal of haematology, 1989-05, Vol.42 (5), p.425-430

1989

Volltextzugriff (PDF)

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors

Blood, 1990-10, Vol.76 (7), p.1349-1354

1990

Volltextzugriff (PDF)

Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alpha

Leukemia & lymphoma, 1990, Vol.1 (5-6), p.341-352

1990

Volltextzugriff (PDF)

Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alphadagger

Leukemia & lymphoma, 1990, Vol.1 (5-6), p.341-352

1990

Volltextzugriff (PDF)

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia : defective LAK generation and reduced susceptibility of the leukemic cells to allogeceic and autologous LAK effectors

Blood, 1990, Vol.76 (7), p.1349-1354

1990

Volltextzugriff (PDF)

Pleural effusion in a case of non-Hodgkin's lymphoma: diagnostic use of molecular analysis

Recenti progressi in medicina, 1990-09, Vol.81 (9), p.568

1990

Volltextzugriff (PDF)

Scleroderma and hairy-cell leukemia

European journal of haematology, 1994, Vol.52 (3), p.189-190

1994

Volltextzugriff (PDF)

Wear and Corrosion Behavior of HVOF-Sprayed WC-CoCr Coatings on Al Alloys

Journal of thermal spray technology, 2010, Vol.19 (1-2), p.358-367

2010

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(29)
Berichte
(1)

Sprache

Englisch
(28)
Italienisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(13)
Science & Technology
(11)
Life Sciences & Biomedicine
(9)
Hematology
(8)
Biological And Medical Sciences
(6)
Male
(6)
Medical Sciences
(6)
Aged
(5)
Hematologic And Hematopoietic Diseases
(4)
Hematology, Oncology And Palliative Medicine
(4)
Adult
(3)
Cell Line
(3)
Cytotoxicity, Immunologic
(3)
Female
(3)
Immunotherapy
(3)
Interleukin-2 - Pharmacology
(3)
Killer Cells, Natural - Immunology
(3)
Middle Aged
(3)
Oncology
(3)
Aged, 80 And Over
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study

O-020 Erythropoietin alpha therapy in 1110 lower-risk MDS patients: A real life survey from the network of regional Italian MDS Registries

P104 Prognostic role of transfusion requirement in myelodysplastic syndromes

P002 Clinical and epidemiological considerations on myelodysplastic syndromes (MDS). The experience of the Piedmont MDS Register

93 - Effects of Erythropoiesis-Stimulating Agents on Overall Survival of IPSS Low/INT-1 Risk Transfusion Independent Myelodysplastic Syndrome Patients, a FISM Study

In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity

Interleukin 2 does not promote the in vitro and in vivo proliferation and growth of human acute leukaemia cells of myeloid and lymphoid origin

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors

Scleroderma and hairy-cell leukemia

Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry

Effect of alpha-interferon on the immune system of patients with hairy cell leukemia

Lymphokine activated killer (LAK) activity in lymphoproliferative disorders

Defective Lymphokine-Activated Killer Cell Generation and Activity in Acute Leukemia Patients With Active Disease

Autocrine or paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia

Immunoregulatory T-cell defects in B-cell chronic lymphocytic leukemia: cause or consequence of the disease? The contributory role of decreased availability of interleukin 2 (IL-2)

Treatment of hairy-cell leukaemia with α-interferon (α-IFN)

Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease

Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors

Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alpha

Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alphadagger

Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia : defective LAK generation and reduced susceptibility of the leukemic cells to allogeceic and autologous LAK effectors

Pleural effusion in a case of non-Hodgkin's lymphoma: diagnostic use of molecular analysis

Scleroderma and hairy-cell leukemia

Wear and Corrosion Behavior of HVOF-Sprayed WC-CoCr Coatings on Al Alloys

Suchergebnisse filtern